Table of contents:
Video: The Economic Burden Of HPV-related Diseases In Russia Has Exceeded 60 Billion Rubles
The economic burden of HPV-related diseases in Russia has exceeded 60 billion rubles
The results of a large-scale study of the economic and socio-demographic burden of diseases associated with human papillomavirus and the economic efficiency of vaccination against human papillomavirus in Russia are published. The study showed that vaccination of 12-year-old girls against HPV in our country is a cost-effective preventive measure.
Photo: pixabay.com /
The results of a large-scale study of the economic and socio-demographic burden of diseases associated with human papillomavirus (HPV) and the cost-effectiveness of vaccination against HPV in Russia have been published. The study showed that vaccination of 12-year-old girls against HPV in our country is a cost-effective measure of disease prevention.
Earlier, Mednews talked about an international study that provided compelling evidence that HPV vaccination effectively prevents cervical cancer and can help eliminate it.
The Russian study is a comprehensive modeling based on epidemiological data on morbidity and mortality from HPV-associated diseases. The model for assessing the effectiveness of HPV vaccination is based on an analysis of direct and indirect economic and socio-demographic damage. And this damage significantly exceeds the cost of immunization: today, in the absence of vaccination at the national level, the annual economic burden of diseases associated with the virus is 63.6 billion rubles.
At the same time, according to the study model, if 70% of girls aged 12 are covered with HPV vaccination, the economic burden of disease will decrease by 41.7 billion rubles. per year, 4,841 deaths from malignant neoplasms caused by HPV will be prevented, and the birth rate will increase by 1,100 children per year. If one girl is vaccinated, the preventable damage will amount to 13,327 rubles. The total budget savings for the entire modeling period (total economic effect), taking into account the cost of vaccination, will amount to 31.6 billion rubles.
HPV is one of the most common viruses and causes a wide range of diseases. More than 7.5% of all cancer deaths in women are caused by this particular virus. Vaccination against HPV is recommended by WHO for priority inclusion in the national immunization schedules of all countries of the world. Today, more than 90 countries are already vaccinating their citizens against HPV.
Russian experts insist on the need to make a decision on the prevention of HPV infection at the federal level. Today in Russia there are targeted regional screening and vaccination programs, there are vaccines registered in Russia, but this is not enough to turn the tide. The most painful issue is the question of price: at the first stage, the state's costs will be significant, and the economic effect will manifest itself only after ten years.